Recon: Novo Nordisk to slash Wegovy price by as much as 37% in India; Neurocrine depression therapy fails in mid-stage study
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsUnited StatesReconJason ScottBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsUnited States